Bethanechol

Article Details

Citation

Copy to clipboard

Padda IS, Derian A

Bethanechol

.

PubMed ID

32809422 [ View in PubMed

]

Abstract

Bethanechol is FDA approved for the treatment of postoperative urinary retention, postpartum urinary retention, and overflow incontinence caused by neurogenic atony of the bladder. It is in the parasympathomimetic class of drugs. This activity reviews the indications, action, and contraindications for bethanechol as a valuable agent in the management of nonobstructive urinary retention related disorders when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent to members of the interprofessional team in the management of patients with nonobstructive urinary retention and related conditions.

DrugBank Data that Cites this Article

Drugs

Bethanechol

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Bethanechol	Muscarinic acetylcholine receptor M1	Protein	Humans	Unknown	Agonist	Details
Bethanechol	Muscarinic acetylcholine receptor M2	Protein	Humans	Unknown	Agonist	Details
Bethanechol	Muscarinic acetylcholine receptor M3	Protein	Humans	Yes	Agonist	Details
Bethanechol	Muscarinic acetylcholine receptor M4	Protein	Humans	Unknown	Agonist	Details
Bethanechol	Muscarinic acetylcholine receptor M5	Protein	Humans	Unknown	Agonist	Details